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Abstract
Redox state is a critical determinant of cell function, and any major imbalances can cause severe damage or death.
Objectives: The aim of this study is to determine if AMP-activated protein kinase (AMPK), a cellular energy sensor, is
activated by oxidants generated by Berberine in endothelial cells (EC).
Methods: Bovine aortic endothelial cells (BAEC) were exposed to Berberine. AMPK activity and reactive oxygen species were
monitored after the incubation.
Results: In BAEC, Berberine caused a dose- and time-dependent increase in the phosphorylation of AMPK at Thr172 and
acetyl CoA carboxylase (ACC) at Ser79, a well characterized downstream target of AMPK. Concomitantly, Berberine increased
peroxynitrite, a potent oxidant formed by simultaneous generation of superoxide and nitric oxide. Pre-incubation of BAEC
with anti-oxidants markedly attenuated Berberine-enhanced phosphorylation of both AMPK and ACC. Consistently,
adenoviral expression of superoxide dismutase and pretreatment of L-N
G-Nitroarginine methyl ester (L-NAME; a non-
selective NOS inhibitor) blunted Berberine-induced phosphorylation of AMPK. Furthermore, mitochondria-targeted tempol
(mito-tempol) pretreatment or expression of uncoupling protein attenuated AMPK activation caused by Berberine.
Depletion of mitochondria abolished the effects of Berberine on AMPK in EC. Finally, Berberine significantly increased the
phosphorylation of LKB1 at Ser307 and gene silencing of LKB1 attenuated Berberine-enhanced AMPK Thr172
phosphorylation in BAEC.
Conclusion: Our results suggest that mitochondria-derived superoxide anions and peroxynitrite are required for Berberine-
induced AMPK activation in endothelial cells.
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Introduction
AMP-activated protein kinase (AMPK), a heterotrimeric
complex comprised of a catalytic subunit a and two regulatory
subunits, b and c, is an evolutionarily conserved serine/threonine
protein kinase that is ubiquitously expressed. It was initially
characterized as a ‘‘fuel gauge’’, modulating cellular energy flux in
eukaryotic cells in response to changes of AMP:ATP ratios [1,2,3].
AMPK can be activated by conditions that increase intracellular
AMP such as exercise [4], hypoxia [5], hypoglycemia [6], as well
as certain cytokines and drugs such as leptin [7], adiponectin [8],
metformin [9], statins [10] and rosiglitazone [11]. The primary
mechanism responsible for AMPK activation involves phosphor-
ylation of AMPK at Thr172 residue located within the activation
loop of a subunits [12]. Activation of AMPK has been linked to
numerous energy-conserving cellular processes, such as promotion
of glucose uptake and glucose transportation [13]; stimulation of
glycogen, cholesterol, fatty acid, triacylglycerol synthesis, glucose
and fatty acid oxidation [14]; and acceleration of mitochondrial
biogenesis [15]. In addition to its roles in energy homeostasis,
more recent studies have identified some broader protective roles
for AMPK in atherosclerosis [16] and inflammation [17] as well as
some beneficial angiogenic effects [18,19].
Berberine [a naturally yellow colored compound with molecular
name 18, 5,6-dihydro-9,10-dimethoxybenzo(g)-1,3-benzodiox-
olo(5,6-a) quinolizinium], is a benzyl tetra isoquinoline plant
alkaloid derived from the Berberidaceae family. It has been used
as a nonprescription oral drug to treat gut infections and diarrhea
with few side effects in traditional Chinese Medicine and Native
American remedies for many centuries. Recently, Berberine has
been shown to possess many pharmacological properties, such as
anti-inflammatory [17], anti-hypertensive [20], and anti-prolifer-
ative/anti-tumor [21] activity. It has also been reported that
Berberine has some beneficial effects when used adjunctively for
metabolic disorders including obesity, hyperlipidemia, hypercho-
lestrolemia, hyperglycemia, and also displays insulin-sensitizing
properties in rodent models of insulin resistance and diabetes. It
significantly improves glucose tolerance, and enhances insulin
action in obese and/or diabetic subjects [22,23]. These beneficial
effects are related in part to the ability of Berberine to activate
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inhibiting respiratory complex I, a similar effect to metformin and
rosiglitazone [24]. However, the precise mechanism by which
Berberine activates AMPK has not been established. The aim of
our study was to identify the underlying mechanism of Berberine-
induced AMPK activation.
Reactive oxygen and nitrogen species (ROS and RNS) such as
superoxide anions (O2
2), hydrogen peroxide (H2O2), and
peroxynitrite (ONOO
2) are small and highly reactive molecules
having both physiological and pathological effects [25]. Normal
cellular ROS concentrations play important roles in cell signaling
pathways and are vital for physiological functions. Peroxynitrite
(ONOO
2) is a highly reactive ROS formed by O2
2 and NO. It
has been demonstrated that metformin inhibits complex I of the
respiratory chain to generate mitochondrial O2
2, and then
ONOO
2, which leads to AMPK activation via a c-Src and
PI3K-dependent pathway [26]. Our data indicate that Berberine-
induced AMPK activation is mediated by mitochondria-derived
superoxide and peroxynitrite in endothelial cells (EC).
Materials and Methods
Materials
Human umbilical vein endothelial cells (HUVEC) and bovine
aortic endothelial cells (BAEC) were purchased from American
Type Culture Collection (Rockville, MD), cell culture media were
purchased from Lonza Group Ltd. (Switzerland). Berberine,
ethidium bromide, sodium pyruvate, uridine, and L-nitroarginine
methyl ester (L-NAME) were obtained from Sigma-Aldrich Inc. (St.
Louis, MO). Dihydroethidium (DHE) and dihydrorhodamine-123
(DHR) were obtained from Invitrogen Corporation (Carlsbad, CA).
Antibodies against phospho-AMPK a (Thr172), AMPK a,
phospho-Acetyl-CoA carboxylase (ACC) (Ser79) and b-actin were
from Cell Signaling (Beverly, MA). Antibody raised against SOD
wasobtained from Santa Cruz Biotechnology Inc (Santa Cruz, CA).
Antibody against UCP2 was from Alpha Diagnostic Intl. Inc. (San
Antonio, TX). RNeasy Mini Kit and RNA UltraSense One-Step
RT-PCR System were obtained from Qiagen Inc (Valencia, CA).
Cell culture
HUVEC were cultured in endothelial basal media (EBM) with
EGM
TM SingleQuots from LONZA (Walkersville, MD) [27]. The
medium was changed every 2 days before the cells reached
confluence. Cells were incubated in a humidified atmosphere of
5% CO2/95% air at 37uC. BAEC were grown in EBM
supplemented with 2% fetal bovine serum. To generate mito-
chondria-depleted BAEC (ru cells), wild-type BAEC were
incubated in medium containing ethidium bromide (50 ng/ml),
sodium pyruvate (1 mM), and uridine (50 mg/ml) for 3 weeks, as
described previously [26]. The ru status of cells was confirmed by
the absence of cytochrome c oxidase subunit II by RT-PCR.
Measurement of cellular ATP, ADP, and AMP
After being treated with Berberine or vehicle, HUVEC (100-
cm
2 dishes) were immediately washed with ice-cold PBS, then
scraped with HClO4, and centrifuged at 4uC (5 min, 14,000 rpm).
After centrifugation, the supernatants were neutralized by KOH.
The supernatants were detected by HPLC to determine the
contents of ATP, ADP, and AMP.
Detection of superoxide anions
Intracellular O2
2 was measured using the dihydroethidium
(DHE) fluorescence/high-performance liquid chromatography
(HPLC) assay with minor modifications [28]. Briefly, BAEC were
incubated with 0.5 mM DHE for 30 min, and then extracted with
30% methanol. Oxyethidium (a product of DHE and O2
2) and
ethidium (a product of DHE auto-oxidation) were separated and
quantified using a C-18 HPLC column (mobile phase: gradient of
acetonitrile and 0.1% trifluoroacetic acid). O2
2 production was
determined by the conversion of DHE into oxyethidium.
Measurement of peroxynitrite
ONOO
2 generation in BAEC after Berberine treatment was
determined using chemiluminescence detection by formation of
the fluorescent dye rhodamine 123 (RH) from dihydrorhodamine
123 (DHR). 5 mM DHR was added into culture medium, after
1 hour incubation, 200 ml medium was added into 96-well plate,
and fluorescence was measured at 570 nm with excitation at
500 nm. Since DHR slowly auto oxidizes to RH, background
fluorescence in medium alone was subtracted from the measured
values with ONOO
2.
Adenovirus infection
BAEC or HUVEC were infected in EBM with EGM
TM
SingleQuots for 48 hours with adenovirus encoding green
fluorescence protein (GFP), superoxide dismutase 1 (SOD1) or
catalase. Adenoviruses encoding GFP served as control, and
transfection efficiency was typically .80% as determined by GFP
expression.
Western blot
Western blotting assays were done as described previously [29].
The primary antibodies were polyclonal and raised against p-
AMPK-Thr172 (1:1000), p-ACC-Ser79 (1:1000), AMPK (1:1000),
SOD1 (1:1000), UCP2 (1:1000), and b-actin (1:3000). The
intensity (area density) of the individual bands on Western blots
was measured by densitometry (model GS-700, Imaging Densi-
tometer; Bio-Rad). The background was subtracted from the
calculated area.
Reverse transcription–polymerase chain reaction (RT-
PCR)
Total cellular RNA was isolated from treated HUVEC with
the total RNA isolation protocol for the RNeasy Mini Kit
RNA. The procedures for semi-quantitative reverse transcription-
polymerase chain reaction (RT-PCR) were performed by using
forward (59-GCCATGCAGTACTTCACCAA-39) and reverse
(59-AGGCTTCTGTGATGGCCACCG-39) primers correspond-
ing to bovine cytochrome c oxidase subunit II mRNA according to
the manufacturer’s recommendations. Reactions were run for 20
cycles at conditions as follows: denaturation for 30 seconds at
94uC, annealing for 30 seconds at 55uC, and extension for 40
seconds at 72uC. Constitutively expressed glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) mRNA was amplified as
internal control.
Statistical analysis
Statistical comparisons were performed using a Student’s t test
or one-way ANOVA with Bonferroni’s procedure for post hoc
analysis. Values of p,0.05 were considered significant.
Results
Berberine causes a dose- and time-dependent increase in
AMPK in EC
To investigate whether ONOO
2 is critical to Berberine
activated AMPK and its downstream target, ACC in EC,
AMPK and Redox Regulation
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Berberine (0, 1, 5, 10, 20, 50, 100, 200 mM) for 2 h. AMPK
activation was evaluated by monitoring the phosphorylation of
AMPK at Thr172 and ACC at Ser79. As shown in Fig. 1A and B,
Berberine increased the phosphorylation of AMPK-Thr172 and
ACC-Ser79 in a dose-dependent manner. Furthermore, activation
of AMPK by Berberine was also time-dependent. 10 mM
Berberine increased the phosphorylation of AMPK-Thr172 and
ACC-Ser79 as early as 30 minutes, reaching a peak value at about
60 minutes without affecting the total content of AMPK (Fig. 1C).
Because 10 mM of Berberine caused AMPK activation dramati-
cally, we used this concentration of the compound for subsequent
experiments.
Effects of Berberine on AMP/ATP ratios
We next determined if AMPK activation by Berberine was due
to the changes of AMP/ATP ratio. As depicted in Fig. 2A, the
AMP/ATP ratio didn’t change until 60 min incubation of
Berberine (10 mM), suggesting changes in AMP/ATP ratios occur
only at late stage of Berberine incubation (.1 h).
Berberine increases intracellular superoxide
Our previous studies have shown that redox signaling plays an
important role in AMPK activation [26,30,31]. In order to
investigate whether endogenous superoxide was also involved in
AMPK activation caused by Berberine, the generation of
intracellular superoxide was assessed by using DHE/HPLC assay.
As shown in Fig. 2B, exposure of BAEC to Berberine (10 mM), a
concentration at which AMPK was activated, also significantly
increased DHE fluorescence as early as 30 min after treatment
and superoxide release continued to rise when incubation
prolonged (Figure 2B), indicating that Berberine triggered
intracellular superoxide generation.
Anti-oxidants attenuate Berberine-induced AMPK
activation in EC
We next evaluated if antioxidants altered Berberine-induced
AMPK activation. Pre-incubation with antioxidant reagents (NAc,
DTT and tempol) significantly attenuated AMPK activation
caused by Berberine (Fig. 2C and 2D). This implies that reactive
oxygen species are involved in the AMPK activation process
induced by Berberine.
Activation of AMPK by Berberine is peroxynitrite-
dependent
Since simultaneous generation of both O2
2 and NO increases
the formation of ONOO
2 and our previous studies [30,31,32]
have also demonstrated that ONOO
2 activates AMPK, we sought
to investigate if endogenous ONOO
2 was involved in this process.
To this end, the effects of Berberine on AMPK activity were
monitored under conditions where ONOO
2 production was
inhibited. SOD1 was overexpressed in BAEC (to scavenge O2
2)o r
pre-treated with L-NAME (1 mM; to inhibit NO production).
Adenoviral expression of SOD1 dramatically increased the levels
of SOD1 in BAEC compared with GFP infection (Figure 3A).
Interestingly, adenoviral overexpression of SOD1 markedly
attenuated Berberine-induced AMPK Thr172 phosphorylation
(Fig. 3A and 3B). In contrast, adenoviral overexpression of
catalase, an enzyme detoxifying H2O2, had no effects on
Berberine-enhanced AMPK activation in BAEC (Fig. 3A and
3B), suggesting that H2O2 is not involved in AMPK activation by
this compound. Similarly, pre-treatment with L-NAME, a non-
selective NOS inhibitor, did not alter the basal levels of AMPK
phosphorylation at Thr172 (Fig. 3C and 3D), but L-NAME
abolished the effects of Berberine on the phosphorylation of
AMPK at Thr172 and ACC at Ser79 (Fig. 3C and 3D).
Figure 1. Effects of Berberine on the phosphorylation of AMPK-Thr 172 and ACC-Ser79, AMP/ATP ratios, and superoxide
production in BAEC. A&B , Dose-dependent increase of of AMPK-Thr172 and Ser79 phosphorylation by berberine in BAEC. Confluent BAEC were
incubated with different doses of Berberine (1 mM to 200 mM) for 2 h. The blot is representative of three individual experiments. n=3 *p,0.05,
control versus Berberine-treated. C&D , Time-dependent increase of AMP-Thr172 and Ser79 by Berberine (10 mM) in BAEC. The blot is representative
of three blots obtained from three separate experiments. n=3 * p,0.05, control versus Berberine-treated.
doi:10.1371/journal.pone.0015420.g001
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2 altered the effects of
Berberine. Uric acid is a widely used scavenger of ONOO
2. The
production of intracellular ONOO
2 was directly inhibited by this
scavenger and AMPK-Thr172 phosphorylation was detected
under this condition (Fig. 3E and 3F). The data show AMPK
phosphorylation at Thr172 was inhibited by uric acid pretreatment.
Figure 2. Activation of AMPK by Berberine is mediated by reactive oxygen species (ROS). A, Time-course of Berberine (10 mM) on AMP/
ATP ratios in BAEC. After exposure to Berberine (10 mM) for the time indicated, BAEC were subjected to HPLC assays to measure the AMP/ATP ratio.
n=5, *p,0.05, control versus Berberine-treated. B, Time-dependent increase of superoxide anions caused by Berberine (10 mM) in BAEC. After
incubation with Berberine (10 mM) for the time indicated, intracellular ROS were detected by the DHE fluorescence/HPLC assay as described in
‘‘Materials and Methods.’’ n=5, *p,0.05, control versus Berberine-treated. C, BAEC were pre-treated with anti-oxidants tempol (10 mM), NAc (2 mM),
or DTT (1 mM) for 30 min, and then treated with Berberine for 2 h. D, Summary data for the effects of anti-oxidants n=5 *p,0.05, control versus
Berberine-treated, # p,0.05, Berberine alone versus Berberine with one or the other of the two anti-oxidants.
doi:10.1371/journal.pone.0015420.g002
Figure 3. Activation of AMPK by Berberine is ONOO
2-dependent. A&B , Effects of adenoviral overexpression of SOD and catalase on
Berberine-induced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC. BAEC were transfected with adenovirus overexpressed with SOD,
catalase or GFP (50 MOI) for 24 h. n=4, *p,0.05 control versus Berberine-treated). C&D , Effects of L-NAME on Berberine-induced phosphorylation of
AMPK-Thr172 and ACC-Ser79 in BAEC. BAEC were pre-treated with the eNOS inhibitor L-NAME (1 mM) for 30 min. Thereafter BAEC were treated with
Berberine (10 mM) for 2 h. n=3, *p,0.05; E&F , Effects of uric acid on Berberine-induced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC.
BAEC were pretreated with the ONOO
2 scavenger, uric acid (0.5 mM) for 30 min, and then treated with Berberine (10 mM) for 2 h. n=4, *p,0.05,
control versus Berberine-treated, # p,0.05, Berberine alone versus Berberine plus uric acid. G, Berberine increases the formation of ONOO
2 in BAEC.
After 10 mM Berberine treatment for the time indicated and DHR (5 mM) incubation for 1 hr, the production of ONOO
2 was determined by DHR
oxidation. n=4 *p,0.05 control versus Berberine-treated. G. Effects of adenoviral overexpression of SOD or L-NAME on the formation of ONOO
2
caused by berberine in BAEC. After Berberine (10 mM) treatment for the time indicated and DHR (5 mM) incubation for 1 hour, the production of
ONOO
2 was determined by DHR oxidation. n=4 *p,0.05 control versus Berberine-treated.
doi:10.1371/journal.pone.0015420.g003
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2, its synthesis was
measured after incubation with Berberine. ONOO
2 production
was increased significantly as early as 30 min following incubation
(Fig. 3G). Further, either adenoviral overexpression of SOD or L-
NAME administration of L-NAME, ablated berberine-induced
ONOO- formation in EC (Figure 3H). Taken together, our result
suggest that berberine increased the formation of ONOO
2.
Identification of mitochondria as the source of
superoxide anions
We next identified the source of oxidants by which Berberine
activated AMPK in BAEC. Increasing evidence suggests that
NAD(P)H oxidases, xanthine oxidase, and mitochondria are major
sources of superoxide in endothelial cells [33]. Pre-incubation of
allopurinol and oxypurinol (two potent inhibitors for xanthine
oxidase) did not alter the effects of Berberine (Figure 4A).
Similarly, ovexpression of p47
phox dominant negative mutants
(p47-DN), a cytosolic and membrane subunit of NAD(P)H oxidase, didn’t
alter AMPK phosphorylation at Thr172 in EC (Figure 4C). This
result was further confirmed by the inability of overexpression of
p67
phox dominant negative mutants, another subunit of NAD(P)H
oxidase 9 (data not shown). Taken together, our results exclude the
possibility of NAD(P)H oxidase as a potential source of oxidants
provoked by Berberine treatment. In contrast, pre-incubation of
mitochondria-targeted tempol, which inhibits oxidant formation
from mitochondria, attenuated Berberine-enhanced phosphoryla-
tion of AMPK at Thr172 and ACC at Ser79 in BAEC (Figure 4C
and 4D), implying that mitochondria might a source of superoxide
in Berberine-treated EC.
Mitochondrial uncoupling protein 2 (UCP2), an inner mem-
brane mitochondrial protein, has been implicated in superoxide
modulation. It was interesting to test if gene silencing of UCP2
accentuated the effects of Berberine on AMPK. BAEC were
transfected with UCP2 siRNA or control siRNA. As depicted in
Fig. 4E and 4F, gene silencing of UCP2 increased the
phosphorylation of AMPK at Thr172. Importantly, transfection
of UCP2-specific siRNA but not control siRNA, accentuated the
effects of Berberine on AMPK phosphorylation at Thr172
(Figure 4E and 4F). Conversely, adenoviral overexpression of
UCP-2 accentuated Berberine-enhanced AMPK phosphorylation
at Thr172 in EC (Figure 4G). Taken together, these results
support a role of mitochondrial superoxide in the effects of Berberine
on AMPK.
Berberine fails to activate AMPK in mitochondria-deleted
ru-BAEC
To further confirm if mitochondrial superoxide was required for
these Berberine-induced effects, we created BAEC without
functional mitochondria (ru cells). After BAEC were incubated
with mitochondria deleting conditional medium for 3 weeks,
BAEC dramatically reduced the expression of cytochrome c
oxidase subunit II at the mRNA levels detected by RT-PCR
(Fig. 5A), confirming a deficiency of mitochondria in ru BAEC.
Subsequently we tested if Berberine increases intracellular
superoxide in ru-BAEC. We confirmed our expectation in the
demonstration that Berberine did increase superoxide production in
wild-type BAEC, but failed to do so in mitochondria-deleted ru-
BAEC, as assayed by DHE staining (Figure 5B). Further, as
predicted, Berberine also increased the phosphorylation of AMPK
at Thr172 and ACC at Ser79 in BAEC. However, it failed to
increase AMPK phosphorylation in ru-BAEC (Fig. 5C and D).
It was provocative to determine if AMPK in ru BAEC could be
activated by exogenous ONOO
2. Both BAEC and ru BAEC were
therefore exposed to chemically synthesized ONOO
2 (50 mM) for
5 min. Figure 5C show that ONOO
2 caused activation of AMPK
in both BAEC and ru BAEC to a similar degree, suggesting that
the response to ONOO
2 in ru BAEC remained unchanged
compared to BAEC. Thus, the decrease of AMPK activation in ru
Figure 4. Reactive oxygen species (ROS) involved in Berberine induced AMPK activation are derived from mitochondria. A, Effects of
xanthine oxidase inhibitors, allopurinol and oxypurinol, on Berberine-enhanced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC. BAEC were
pre-treated with mitochondrial tempol (50 mM) for 30 min, and then treated with Berberine (10 mM) for 2 h. The blots are representative of three
independent experiments. B, Effects of adenoviral overexpression of p47phox dominant negative mutants on Berberine-enhanced phosphorylation
of AMPK-Thr172 and ACC-Ser79 in BAEC. The blots are representative of three independent experiments. C&D , Effects of mitochondrial tempol
(*p,0.05, control versus Berberine-treated, #p,0.05, Berberine-alone versus Berberine plus mitochondrial tempol). E&F , Effects of UCP-2 siRNA
transfection on Berberine-enhanced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC. BAEC were transfected with UCP2 siRNA for 24 hr, and
then treated with Berberine (10 mM) for 2 hr. n=3, *p,0.05, control versus Berberine-treated, # p,0.05, Berberine-alone versus Berberine plus UCP2
siRNA.G. Effects of adenoviral overexpression of UCP-2 on Berberine-enhanced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC. n=3
*p,0.05, control versus UCP-2; #p,0.05, control verus Berberine-alone; +p,0.05 Berberine-treated versus Berberine plus UCP2.
doi:10.1371/journal.pone.0015420.g004
AMPK and Redox Regulation
PLoS ONE | www.plosone.org 5 November 2010 | Volume 5 | Issue 11 | e15420BAEC is likely due to its attenuation of ONOO
2 production in ru
BAEC in response to Berberine.
Exogenous ONOO
2 inhibits AMPK activity in vitro
To exclude a direct effect of ONOO
2 on AMPK, recombinant
AMPK was exposed to chemically synthesized ONOO
2 in vitro.
After the treatment, AMPK activity was assayed. Unexpectedly,
ONOO
2 caused a dose-dependent inhibition of AMPK activity,
suggesting a direct inhibitory effect of ONOO
2 on AMPK
(Figure 6A). This suggests that ONOO
2 might exert opposite
effects on AMPK activity, i.e., AMPK activation via upstream
enzymes and AMPK suppression via an unknown posttransla-
tional modification by ONOO
2.
PP2A is not required for Berberbine-induced AMPK
activation
PP2A is reported to regulate AMPK activation [34]. We next
determined if PP2A inhibition with pharmacological or genetic
means altered Berberine-induced AMPK phosphorylation. As
depicted in Figure 3B, OA pretreatment had no effect on
Berberine-induced phosphorylation of AMPK-Thr172 and ACC
at Ser79. Concomitantly, transfection of PP2A siRNA didn’t
attenuate the phosphorylation of AMPK or ACC, suggesting that
the effect of Berberine was PP2A independent.
STO609 treatment does not alter Berberine-enhanced
phosphorylation of AMPK and ACC in EC
Calcium calmodulin protein kinase II (CAMKK II) is reported
to be an upstream kinase for nitric oxide-induced AMPK
activation [35]. We next assayed the contribution of CaMKKII
in berberine-induced AMPK activation. As shown in Figure 6D,
pretreatment of STO-609 (100 nM) had no effect on Berberine-
enhanced AMPK phosphorylation in EC.
Berberine increases LKB1 phosphorylation at Serine 307
in EC
LKB1 is a known upstream kinase of AMPK. Phosphorylation
of Ser307 is reported for metformin-induced AMPK activation in
endothelial cells [36]. Thus, we next determined if Berberine
altered LKB1 phosphorylation at Serine 307. As shown in
Figure 6E, Berberine markedly increased the detection of LKB1
phosphorylation at Serine 307 (Figure 6E), which was paralleled
with increased AMPK phosphorylation at Thr172 (Figure 6E).
Further, transfection of LKB1 siRNA abolished Berberine-
enhanced AMPK phosphorylation in EC (Figure 6F). Finally,
Berberine had no effects on AMPK Thr172 phosphorylation in
LKB1 deficient A549 cells (Figure 6G). Taken together, our results
imply that LKB1 was required for Berberine-induced AMPK
phosphorylation.
Discussion
In this study, we observed that mitochondria derived superoxide
and peroxynitrite are required for Berberine-induced AMPK
activation (Fig. 6). The key evidence can be summarized as follows:
(1) Exposure of BAEC to Berberine at the dose required for
AMPK-Thr172 phosphorylation significantly increased intracel-
lular O2
2 and ONOO
2 production. Although Berberine
increased intracellular AMP/ATP ratio after 1 h of incubation,
intracellular O2
2 and ONOO
2 production was increased at about
30 min incubation, suggesting that this time frame adequately
allows oxygen and nitrogen species to initiate AMPK activation.
(2) Inhibition of ONOO
2 formation by overexpression of SOD1
Figure 5. Mitochondria depletion abolishes Berberine-induced AMPK phosphorylation in endothelial cells. Confluent monolayers of
BAEC were incubated in EGM with 2% fetal bovine serum alone or in ru medium as described in ‘‘Materials and Methods.’’ A, After incubation, BAEC
were harvested, total RNA were extracted, and mRNA for cytochrome c oxidase subunit II (CytOxII) were estimated by RT-PCR. Data are representative
of three independent experiments. B, BAEC and ru cells were treated with Berberine (10 mM) for 30 min; the production of ROS was detected by DHE/
HPLC assay. C & D. Effects of mitochondria depletion on AMPK-Thr172 phosphorylation caused by Berberine and ONOO-. BAEC and ru cells were
treated with Berberine (10 mM) for 2 h or ONOO
2 (50 mM) for 15 min, after treatment, cells were lysed and proteins were separated by SDS-PAGE and
Western blots. n=3 *p,0.05, control versus Berberine-treated.
doi:10.1371/journal.pone.0015420.g005
AMPK and Redox Regulation
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2), or incubation with L-NAME (to prevent NO
production), attenuated Berberine-induced AMPK phosphoryla-
tion. (3) When BAEC were pre-treated with uric acid (an ONOO
2
scavenger), the AMPK phosphorylation induced by Berberine was
abolished. (4) Exposure of BAEC to mitochondrial tempol (which
blocks O2
2 release from mitochondria), also blocked Bereberine-
induced AMPK phosphorylation. In contrast, incubation with
allopurinol, oxypurinol or overexpression with adenovirus encod-
ing p47
phox-DN, did not alter Berberine induced AMPK
activation. These results suggest that mitochondria, rather than
xanthine oxidase or NAD(P)H oxidase, were the major source of
superoxide in cells exposed to Berberine. (5) When using UCP2
siRNA to knock down the expression of UCP2 (which uncouples
mitochondrial oxidative phosphorylation from ATP production),
Berberine-induced AMPK phosphorylation was further enhanced.
(6) These results were further corroborated by the findings in ru-
BAEC lacking functional mitochondria. Exposure of ru- BAEC to
Berberine neither enhanced intracellular superoxide release nor
AMPK phosphorylation. Cumulatively these results indicate that
activation of AMPK by Berberine is mitochondrial superoxide
dependent.
Another important finding in this study is that the phosphor-
ylation of LKB1 at S307 is involved in LKB1-mediated AMPK
activation induced by berberine. Our published study [36] has
reported that in multiple cell types the signaling pathways engaged
by several physiological stimuli converge upon LKB1 phosphor-
ylation at S307, which directs the nucleocytoplasmic transport of
LKB1 and consequent AMPK activation. However, further
investigation of LKB1 Ser307 phosphorylation is warranted.
The traditional view has been that ROS exert toxic effects by
damaging or killing cells under pathophysiological conditions.
However, growing experimental evidence now suggests that ROS
such as ONOO
2 are required in some physiological processes as
well [25]. It is conceivable that sub-toxic concentrations of ROS/
Figure 6. Increased LKB1 Serine 307 phosphorylation by Berberine in BAEC. A. Inhibition of AMPK activity by ONOO
2. Recombinant
AMPKa1b1c1 was treated with chemically synthetized ONOO- at concentrations indicated for 5 minutes and AMPK activity was assayed as described
in Methods and Materials. N=5 *P,0.05; control verse ONOO
2-treated; B. Effects of okadaic acid (OA) on Berberine-enhanced phosphorylation of
AMPK-Thr172 and ACC-Ser79 in BAEC. The blot is representative of three blots. from three individual experiments. C. Effects of transfection of PP2A
siRNA on Berberine-enhanced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC. The blot is representative of three blots from three
individual experiments. D. Effects of STO-609 on Berberine-enhanced phosphorylation of AMPK-Thr172 and ACC-Ser79 in BAEC. The blot is
representative of three blots. E. Effects of berberine on the phosphorylation of LKB1 serine 307 in BAEC. The blot is representative of three blots from
three individual experiments. F. Genetic inhibition of LKB1 abolishes Berberine-induced phosphorylation of AMPK-Thr172 in BAEC. The blot is
representative of three blots from three individual experiments. G Effects of Berberine on AMPK phosphorylation at Thr172 in LKB1-deficient A549
cells.
doi:10.1371/journal.pone.0015420.g006
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[26,30,37]. Our data demonstrate that Berberine evokes O2
2
release and O2
2 or its derived oxidant, ONOO
2, is required for
Berberine-enhanced AMPK activation. Berberine has been
reported to exert therapeutic effects on diabetes, obesity and
inflammation [17,38,39,40]. Thus, AMPK activation by Berberine
might help explain the beneficial effects in these conditions.
Turner et al [24] reported that Complex I of the respiratory
chain represents a major target of Berberine in its effect of
improving insulin insensitivity (such as in type II diabetes) through
increased AMPK activity. It has also been demonstrated that
Berberine selectively accumulates in mitochondria on K1735-M2
melanoma cells to arrest cell proliferation, causes mitochondrial
fragmentation and depolarization, and oxidative stress [41].
Berberine has been shown to inhibit mitochondrial respiration
and decrease calcium loading capacity through induction of the
mitochondrial permeability transition (MPT) via interactions with
the adenine nucleotide translocator, (ANT) [41,42]. The antitu-
mor effect of Berberine has also been demonstrated to possess a
mitochondrial component [43]. Whether the mitochondrial
complex I is involved in its anti-microbial, anti-arrhythmic or
other pharmacological properties remains unknown. Previous
work from our laboratory has demonstrated that complex I
associated ROS/RNS production is related to many protective
effects observed in therapy using metformin and the statin drugs
[26,30]. Recently, it has also been reported that Berberine
enhances AMPK activity in a variety of cells, such as adipocytes,
tumor cells, macrophages, smooth muscle cells and endothelial
cells [17,23,40,44]). In addition, other investigators have also
shown that AMPK is a major intermediate in facilitating some
beneficial effects of Berberine [17,38,39,45]. Here we have
demonstrated an important role of mitochondria derived super-
oxide and ONOO
2 in Berberine induced AMPK activation.
However, the possibility that this compound might exert its
beneficial metabolic and cardiovascular properties through an
ONOO
2 dependent pathway similar to metformin and the statins
[30], needs to be further investigated.
In summary, we demonstrate for the first time that Berberine
increases mitochondria-derived superoxide and peroxynitrite to
activate AMPK. Activation of AMPK by Berberine can potentially
expand the pharmaceutical role of the compound in the
management of several diverse yet intertwined human pathologies.
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